Rates of CRS in original cilta-cel trial (heavily pre-treated)=95%

Rates of CRS in randomized trial in earlier setting=76%

Anecdotally, as cilta-cel is being given in situations where disease in minimal, increasingly seeing no CRS at all (no prophy toci/steroids given).

Manni Mohyuddin Grandmother’s advice >>> confounded retrospective nutritional epi studies!

There is a lot to celebrate, but always a lot more to learn with every approval.

What clinicians should know about surrogate endpoints

Nice work Côme Bommier Matthew J. Maurer, DMSc

Many great examples woven into a thoughtful piece

ashpublications.org/blood/article/… Blood Journal

My thoughts on ide-cel, cilta-cel, comparing their recent approvals, comparing across trials, cross-over and sequencing, and the use of MRD as an endpoint.

podcasters.spotify.com/pod/show/wolve…

Thanks for having me WolverHeme, love you guys!

#mmsm

Of COURSE I’m going to listen to WolverHeme … ESPECIALLY when they’re breaking down all the new information in myeloma when it comes to #CART .

Everything has changed - and we have much to decide!

Excellent discussion Anthony Perissinotti, Bernie Marini, Manni Mohyuddin 👏

#oncopharm

Adding CARTician to my vocab

Highly educational clinically and great lessons on critical appraisal as well!

A highly listenable and super
educational podcast, featuring Manni Mohyuddin, @berninini, and Anthony Perissinotti on cilta-cel vs ide-cel and MRD as an endpoint for accelerated approval. 🍻

Mike N WolverHeme Ryan Beechinor Bernie Marini Manni Mohyuddin What makes me so happy is to see that patients and loved ones of patients tuned in to listen. This is why we do what we do and why we are so critical of literature. We have a very high bar for what is acceptable for our patients.🙏🏻 thank you

Check out our latest episode 'Myeloma Madness with the Myeloma Man', where Anthony Perissinotti and Bernie Marini discuss the recent FDA approval updates on CAR-T in myeloma with our good friend and myeloma expert Manni Mohyuddin podcasters.spotify.com/pod/show/wolve…

Manni Mohyuddin Great 🧵! Just wondering, do you think the “old” data showing improvements in PFS and OS (!) with Zometa holds true in this era of Quads and excellent deep responses with very prolonged disease remissions? Evidence some times has an expiration date….

Gonna listen to this later today. Can’t wait.

Excellent editorial by Samer Al Hadidi, MD,MS,FACP about use of T-cell redirecting therapy in myeloma precursor conditions.

Tox of talquetamab can be horrendous- my patients recall it long after moving on to diff treatment.

I disagree with studying it in MGUS/SMM

tinyurl.com/4uvs444s

Thanks to my friends Bernie Marini and Anthony Perissinotti for having me on the podcast to discuss recent myeloma updates (CAR-T approvals, MRD).

I am a big fan of this amazing (and entertaining) podcast! WolverHeme

And thanks for excusing my basic choice of drink 😂

#mmsm